文献速递头颈外科鼻科咽喉与嗓音

既往血液系统恶性肿瘤患者头颈癌风险研究

Risk of Head and Neck Cancer in Patients With Prior Hematologic Malignant Tumors.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2019-01-01

该回顾性分析利用美国退伍军人事务部企业数据仓库纳入3093万9656名退伍军人,其中20万7322例有血液系统恶性肿瘤病史,1353例随后诊断为头颈癌。既往血液系统恶性肿瘤与整体呼吸消化道癌风险升高相关(RR 1.6,95%CI 1.5-1.7),多个亚部位风险亦升高,且部分亚部位2年和5年总生存更差。

要点

  • 既往血液系统恶性肿瘤与整体呼吸消化道癌风险升高相关(RR 1.6,95%CI 1.5-1.7)。
  • 鼻窦(RR 3.0)、鼻咽(RR 2.8)、唾液腺(RR 2.8)风险升高最明显。
  • 多个头颈癌亚部位中,有血液系统恶性肿瘤史者2年和5年总生存更差。

核心结论

  • 既往血液系统或相关恶性肿瘤诊断与多个亚部位头颈实体癌风险升高相关。
  • 在多个头颈癌亚部位中,有血液系统恶性肿瘤史的患者2年和5年总生存更差。
  • 作者认为既往血液系统恶性肿瘤可能是头颈癌发生和进展的不良风险因素。

研究设计与样本

  • 回顾性分析,使用美国退伍军人事务部企业数据仓库识别血液系统恶性肿瘤和头颈癌患者。
  • 纳入出生日期在1910年1月1日至1969年12月31日之间的所有患者,队列共3093万9656名退伍军人。
  • 数据分析时间为2018年8月15日至2019年1月31日。
  • 通过门诊问题列表的ICD-9和ICD-10编码确定诊断并按亚部位分组。

主要发现

  • 20万7322例有血液系统恶性肿瘤,其中1353例随后诊断为头颈癌。
  • 既往血液系统恶性肿瘤与整体呼吸消化道癌风险升高相关(RR 1.6,95%CI 1.5-1.7)。
  • 亚部位分析:口腔RR 1.7(95%CI 1.5-1.9)、口咽RR 1.7(95%CI 1.5-1.9)、喉RR 1.3(95%CI 1.2-1.5)、鼻咽RR 2.8(95%CI 2.1-3.9)、鼻窦RR 3.0(95%CI 2.2-4.1)、唾液腺RR 2.8(95%CI 2.4-3.3)、甲状腺RR 2.1(95%CI 1.9-2.4)。
  • 既往血液系统恶性肿瘤与多个亚部位的2年和5年总生存呈负相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: More than 1.3 million people in the United States have a hematologic malignant tumor currently or in remission. Previous studies have demonstrated an increased risk of secondary neoplasms in patients with hematologic malignant tumors, but research specifically on the risk of head and neck solid tumors in patients with prior hematologic malignant tumors is limited. OBJECTIVES: To examine a possible association between prior hematologic malignant tumors and risk of head and neck cancer and to assess the overall survival (OS) among these patients. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis used the Veterans Affairs (VA) Corporate Data Warehouse (CDW) to identify patients with diagnoses of hematologic malignant tumors and head and neck cancers. All patients in the VA CDW with a birthdate between January 1, 1910, and December 31, 1969, were included, for a cohort of 30 939 656 veterans. Data analysis was performed from August 15, 2018, to January 31, 2019. EXPOSURES: Outpatient problem lists were queried for diagnoses of hematologic malignant tumor and associated malignant tumors using International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes to categorize patients by history of hematologic malignant tumors. MAIN OUTCOMES AND MEASURES: Presence of head and neck cancer was determined from ICD-9 and ICD-10 codes of outpatient problem lists, and cancers were grouped by subsite. The OS was determined from date of death or last outpatient visit date. RESULTS: Of 30 939 656 patients (27 636 683 [89.3%] male; 13 971 259 [45.2%] white), 207 322 patients had a hematologic malignant tumor, of whom 1353 were later diagnosed with head and neck cancer. A history of hematologic malignant tumors was significantly associated with overall aerodigestive tract cancer, with a relative risk (RR) of 1.6 (95% CI, 1.5-1.7), as well as oral cavity (RR, 1.7; 95% CI, 1.5-1.9), oropharynx (RR, 1.7; 95% CI, 1.5-1.9), larynx (RR, 1.3; 95% CI, 1.2-1.5), nasopharynx (RR, 2.8; 95% CI, 2.1-3.9), sinonasal (RR, 3.0; 95% CI, 2.2-4.1), salivary gland (RR, 2.8; 95% CI, 2.4-3.3), and thyroid (RR, 2.1; 95% CI, 1.9-2.4) tumors on subsite analysis. A prior hematologic malignant tumor was also negatively associated with 2-year and 5-year OS for multiple subsites. CONCLUSIONS AND RELEVANCE: A prior diagnosis of hematologic or associated malignant tumors was associated with an increased risk of solid head and neck cancers in a range of subsites. In addition, for several head and neck cancer subsites, patients with prior hematologic malignant tumors had worse 2-year and 5-year OS. These results indicate that a prior hematologic malignant tumor may be an adverse risk factor in the development and progression of head and neck cancer.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Mowery A, Conlin M, Clayburgh D, et al. Risk of Head and Neck Cancer in Patients With Prior Hematologic Malignant Tumors. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31045226. doi:10.1001/jamaoto.2019.1012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。